Triple antiviral treatment for COVID-19 in an immunocompromised patient

J Antimicrob Chemother. 2023 Aug 2;78(8):2097-2099. doi: 10.1093/jac/dkad159.

Authors

Chiara Dentone¹, Malgorzata Mikulska^{1

2}, Chiara Sepulcri², Elisa Balletto^{1

2}, Vanessa De Pace³, Sabrina Beltramini⁴, Matteo Bassetti^{1

2}

Affiliations

¹ Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
² Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore, 1, 16132 Genoa, Italy.
³ Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁴ Pharmacology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

PMID: 37229548
DOI: 10.1093/jac/dkad159

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents* / therapeutic use
COVID-19*
Humans
Immunocompromised Host
SARS-CoV-2
Treatment Outcome

Substances

Antiviral Agents